DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20194322

Pattern of tuberculosis among tribal population of Central India with special reference to cartridge based nucleic acid amplification test as diagnostic tool: a descriptive study at tertiary care hospital

Swati B. Gajbhiye, Madhavi V. Madkey, Dilip S. Gedam

Abstract


Background: Tuberculosis (TB) kills close to half a million Indians every year. Lack of reliable rapid diagnostic techniques for TB hampers timely diagnosis and leads to continued disease transmission, causing significant morbidity and mortality. The potential of newly recommended CBNAAT in TB and MDR-TB detection has been underutilized in our area due to lack of awareness regarding the same. Hence we utilized this rapid, logistically simplified test to study the pattern of tuberculosis among tribal population of Central India.

Methods: Descriptive study of suspected TB patients in tertiary care centre from March 2016 to March 2019. Appropriate specimens from suspected TB patients were collected and subjected to CBNAAT and AFB smear to study the pattern of TB and Rifampicin- Resistant(RR) TB  in our area.

Results: CBNAAT detected overall 27% MTB cases; 27.72 % Pulmonary-TB cases as against smear positivity rate of 20.73% whereas 12.74% Extra-pulmonary-TB (EPTB) cases as against smear positivity rate of 1.59%.Overall 94.91% were RiF Sensitive( RS-TB) and 4.58% were RR-TB. Of the 57 (4.16%) HIV-TB coinfected cases; 96.49% were RS-TB and 5.26% were RR-TB. Co-infected patients have high incidence of EPTB(21.05%) involvement  with RR-TB 3.50%. Among EPTB cases; lymph node aspirate and pus provided highest CBNAAT positive cases and almost 90.62% EPTB specimens were RS-TB .

Conclusions: Availability of new diagnostic services has increased early identification of TB and RR-TB. Awareness among physicians regarding diagnostic utility of CBNAAT should be further increased as early identification of possible MDR cases is key to reducing community transmission and treatment initiation, particularly in high-burden, resource-limited settings.  


Keywords


Cartridge Based Nucleic Acid Amplification Test, Extra-pulmonary tuberculosis, Pulmonary tuberculosis

Full Text:

PDF

References


Global tuberculosis report 2016, Introduction. Available at: https://apps.who.int/medicinedocs/documents/s23098en/s23098en.pdf. Accessed 12 Nov 2017

Fundamental of tuberculosis. Global tuberculosis institute. Available at: globaltb.njms.rutgers.edu/downloads/products/Mantoux/FundamentalsofTB.ppt. Accessed on 12 December 2017.

World Health Organization. Tuberculosis Fact Sheet. Fact Sheet No. 104. Available at: http://www.who.int/mediacenter/factsheets/fs104/en/print.html. Accessed on 15 February 2009.

WHO. Global tuberculosis report. 2017 http://www.who.int/tb/publications/global_ report/en/2018.

World Health Organization (WHO). Global Tuberculosis Report 2016. https://apps.who.int/medicinedocs/documents/s23098en/s23098en.pdf.

Weyer K, Mirzayev F, Migliori GB, Gemert WV, D’Ambrosio L, Zignol M. Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. ERJ. 2013;42(1):252-71.

Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol. 2010 Jan;48(1):229-37.

Steingart K. Xpert MTB/RIF test for detection of pulmonary tuberculosis and rifampicin resistance. J Evid Based Med. 2013;6(1):58.

World Health Organization. Global Tuberculosis TB Report 2014. WHO/HTM/TB/2014.08. Geneva, Switzerland: WHO; 2014. Available at: https://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf. Accessed 26 Nov 2017.

Shrestha P, Arjyal A, Caws M, Prajapati KG, Karkey A, Dongol S, et al. The application of GeneXpert MTB/RIF for smear-negative TB diagnosis as a fee-paying service at a South Asian General Hospital. Tuberculosis research and treatment. 2015;2015.

Xpert MTB/RIF implementation manual.Technical and operational ‘how-to’: practical considerations, 2nd ed. Geneva, World Health Organization, 2014. Available at http://www.who.int/tb/laboratory/policy_statements/en/.

Chauhan LS. Drug resistant TB-RNTCP response. Indian J Tuberc.2008;55(1):5-8.

Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014;1:CD009593

Raizada N, Sachdeva KS, Nair AS, Kulsange S, Gupta RS, Thakur R, et al. Catching the missing million: experiences in enhancing TB & DR-TB detection by providing upfront Xpert MTB/RIF testing for people living with HIV in India. PLoS One. 2015;10(2):e0116721.

Kasat S, Biradar M, Deshmukh A, et al. Effectiveness of CBNAAT in the diagnosis of extra-pulmonary tuberculosis. Int J Res Med Sci. 2018 Dec;6(12):3925-8.

Kandi S, Reddy V, Nagraja SB. Diagnosis of pulmonary and Extra-pulmonary Tuberculosis : How best is CBNAAT when compared to conventional methods of TB detection. Pulm. Research and Resp. Med. 2017;4(2):38-41.

Boyles TH, Hughes J, Cox V, Burton R, Meintjes G, Mendelson M. False-positive Xpert(®) MTB/RIF assays in previously treated patients: need for caution in interpreting results. Int J Tuberc Lung Dis.2014;18(7):876-8.

Gupta A, Kulkarni S, Rastogi N, Anupurba S. A study of Mycobacterium tuberculosis genotypic diversity and drug resistance mutations in Varanasi, North India. Indian J Med Res. 2014;139(6):892‑902.

Maurya AK, Singh AK, Kumar M, Umrao J, Kant S, Nag VL, et al. Patterns and trends of multidrug‑resistance tuberculosis. Indian J Med Microbiol. 2013;31:40‑6.

Datta BS, Hassan G, Kadri SM, Qureshi W, Kamili MA, Singh H, et al. Multidrug‑resistant and extensively drug resistant tuberculosis in Kashmir, India. J Infect Dev Ctries. 2009;4(01):19‑23.

Udwadia ZF. Totally drug resistant‑tuberculosis in India: The bad just got worse. J Assoc Chest Physicians. 2016;4(2):41.

Nhu NTQ, Heemskerk D, Thu DA, Chau TTH, Mai NTH, Nghia HDT, et al. Evaluation of Gene Xpert MTB/RIF for Diagnosis of Tuberculous Meningitis. J Clin Microbiol. 2014;52(1):226-33

Deivanayagam CN, Rajasekaran S, Venkatesan R, Mahilmaran A, Ahmed PR, Annadurai S, et al. Prevalence of acquired MDR-TB and HIV co-infection.Indian J Chest Dis Allied Sci. 2002;44: 237-42.

Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. New England J Medicine. 2008 Aug 7;359(6):563-74.

Rao CM, Thakur B, Thakur S, Dash DP. IJRMS. 2018:6(10):3375-80.

Prakasha SR, Suresh G, D’sa IP, Shetty SS, Kumar SG. Mapping the pattern and trends of extra-pulmonary tuberculosis. J Global Infect Dis. 2013 Apr;5(2):54.

Mavila R, Kottarath M, Nair S, Thaha MM. Site predilection of extra-pulmonary tuberculosis: study from a tertiary care centre. Int J Res Med Sci. 2017 Jan 16;3(11):3386-90.

Berger HW, Mejia E. Tuberculosis Pleurisy. Chest. 1973;63(1):88-92.

Sharma SK, Mohan A. Extra-pulmonary tuberculosis. Indian J Med Res. 2004;120:316-53.